Advertisement

Topics

ThromboGenics NV: ONCURIOUS NV acquires unique portfolio of next-generation immuno-oncology assets from VIB

01:40 EDT 1 Sep 2017 | FinanzNachrichten

Leuven, Belgium 1 September 2017 - ONCURIOUS NV, a Belgium-based biotech company focusing on the development of innovative oncology treatments, today announces that it has reached principle agreem...

Original Article: ThromboGenics NV: ONCURIOUS NV acquires unique portfolio of next-generation immuno-oncology assets from VIB

NEXT ARTICLE

More From BioPortfolio on "ThromboGenics NV: ONCURIOUS NV acquires unique portfolio of next-generation immuno-oncology assets from VIB"

Quick Search
Advertisement
 

Relevant Topics

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...